Read more
This book summarizes the present knowledge of oxidative stress in anti-cancer drug-induced cardiotoxicity and covers cell molecular mechanisms, prevention and treatment strategies, drug research, and population experiments. Racial and gender disparities in anticancer therapy-related cardiotoxicity are also covered. Book chapters provide current and timely review of hypothesis-driven research, case studies, and review articles. As such, this book serves as a source of knowledge and guidance for research, clinical prevention, and treatment of cardiotoxic anticancer drugs.
Furthermore, this book is essential for students, cardiologists, cardio-oncologists, and heart failure researchers.
List of contents
Part 1. Epidemiology & Cardiac Signaling.- 1. Risk Factors Associated with Anthracycline Induced Cardiac Dysfunction.- 2. Multilevel Drivers of Disparities in Cardio-oncology.- 3. Cardiotoxicity, Cancer Therapies, and Cardiac Cell Signaling.- 4. Phytochemicals in Cardiotoxicity and Cardioprotection.- Part II. Current Trends in Detection and Management.- 5. Detection, Prevention, & Management of Anthracycline-induced Cardiotoxicity.- 6. Pharmacotherapies in Prevention of Myocardial Oxidative Stress.- 7. Optimizing Cardiovascular Safety: Cardiotoxicity Prevention in Tyrosine Kinase Inhibitor, Monoclonal Antibody, Proteosome Inhibitor, and 5-Fluorouracil Anticancer Therapies.- 8. The Future of Cardio-oncology.
About the author
Sakima A. Smith, MD, MPH, is an associate professor of medicine with tenure at The Ohio State University. He earned his medical degree from Temple University School of Medicine in 2006, completed his internal medicine residency at Barnes-Jewish Hospital/Washington University in 2009, and finished his general cardiology and heart failure/transplant fellowships at Ohio State. In 2014, he also completed a research fellowship and earned a Master’s in Public Health from Ohio State.
Dr. Smith has received several prestigious awards, including the James V. Warren Fellowship Research Award in 2014, the Denman Distinguished Undergraduate Research Mentor Award in 2017, and the Landacre Research Honor Society Distinguished Researcher of the Year in 2019. He established his independent research lab with funding from the Robert Wood Johnson Faculty Development Grant in 2015, the NIH K08 Grant in 2017, and the NIH R01 Grant in 2019. Currently, he holds R01 funding as Principal Investigator, serves as a Co-Investigator on multiple grants, and is Co-PI on a novel T32 postdoctoral fellowship grant.
His research program spans basic cardiovascular research, population health, diversity, and health outcomes. His current R01-funded project in cardio-oncology focuses on understanding how tyrosine kinase inhibitors and other anticancer agents contribute to cardiotoxicity. Dr. Smith’s pioneering work, using both animal and human models, has shown that TKIs can induce adverse cardiac events through multiple mechanisms.
Shane S. Scott, PhD, MS, is an MD/PhD candidate and aspiring cardiothoracic surgeon-scientist at The Ohio State University College of Medicine. He received Bachelor of Science degrees with honors in Chemistry and Biochemistry from Brandeis University in 2013, and a Master of Science degree in Medical Sciences from Boston University School of Medicine in 2018. He recently completed his PhD at The Ohio State University. During his graduate training, Dr. Scott's research was two-fold. First, he explored the role of tyrosine kinase inhibitors in cardiac arrhythmias and heart failure. Second, he investigated the mechanisms by which the absence of cardiac βII-spectrin contributes to the development of arrhythmias, heart failure, and premature death. Dr. Scott is currently a third-year medical student and plans to pursue a residency in cardiothoracic surgery. He was inducted into the Landacre Research Honor Society in 2022 and currently serves as an executive leader of the Ohio State University School of Medicine chapter. He was also recently inducted into the Gold Humanism Honor Society. He has authored several peer-reviewed articles and contributed to multiple book chapters. Myocardial Oxidative Stress in Anti-cancer Therapies and Cardiovascular Disease marks his first volume as lead co-editor.
Summary
This book summarizes the present knowledge of oxidative stress in anti-cancer drug-induced cardiotoxicity and covers cell molecular mechanisms, prevention and treatment strategies, drug research, and population experiments. Racial and gender disparities in anticancer therapy-related cardiotoxicity are also covered. Book chapters provide current and timely review of hypothesis-driven research, case studies, and review articles. As such, this book serves as a source of knowledge and guidance for research, clinical prevention, and treatment of cardiotoxic anticancer drugs.
Furthermore, this book is essential for students, cardiologists, cardio-oncologists, and heart failure researchers.
